摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

6-Methoxy-2-(5-methylfuran-2-yl)-N-((1-methylpiperidin-4-yl)methyl)-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine | 1846570-40-8

中文名称
——
中文别名
——
英文名称
6-Methoxy-2-(5-methylfuran-2-yl)-N-((1-methylpiperidin-4-yl)methyl)-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine
英文别名
6-methoxy-2-(5-methylfuran-2-yl)-N-[(1-methylpiperidin-4-yl)methyl]-7-(3-pyrrolidin-1-ylpropoxy)quinolin-4-amine
6-Methoxy-2-(5-methylfuran-2-yl)-N-((1-methylpiperidin-4-yl)methyl)-7-(3-(pyrrolidin-1-yl)propoxy)quinolin-4-amine化学式
CAS
1846570-40-8
化学式
C29H40N4O3
mdl
——
分子量
492.7
InChiKey
VMMRDFLDWHFNOX-UHFFFAOYSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    4.9
  • 重原子数:
    36
  • 可旋转键数:
    10
  • 环数:
    5.0
  • sp3杂化的碳原子比例:
    0.55
  • 拓扑面积:
    63
  • 氢给体数:
    1
  • 氢受体数:
    7

文献信息

  • [EN] NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES<br/>[FR] NOUVEAUX COMPOSÉS UTILISÉS COMME INHIBITEURS DOUBLES D'HISTONE MÉTHYLTRANSFÉRASES ET D'ADN MÉTHYLTRANSFÉRASES
    申请人:FUNDACIÓN PARA LA INVESTIGACIÓN MÉDICA APLIC
    公开号:WO2015192981A1
    公开(公告)日:2015-12-23
    It relates to the use of compounds of formula (I'), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, as anticancer agents and as agents for generating induced pluripotent stem cells. Compounds of formula (I'), wherein R2' is an alcoxy group, a hydrocarbon chain or a ring system, and R1, R3, and R4 are as defined herein, are dual inhibitors of histone methyltransferases and DNA methyltransferases. It also relates to the compounds of formula (I'), or their pharmaceutically or veterinary acceptable salts, or their stereoisomers or mixtures thereof, wherein R2' is phenyl or 5- to 6-membered heteroaromatic ring, both optionally fused to another rings (i.e., compounds of formula (I)). It also relates to pharmaceutical or veterinary compositions containing compounds of formula (I).
    这里讨论的是使用公式(I')的化合物,或其药用或兽药可接受的盐,或它们的立体异构体或混合物,作为抗癌剂和诱导多能干细胞生成的剂。其中,R2' 是一个醇氧基团、一个碳氢链或一个环系,而 R1、R3 和 R4 如本文所述定义,是组蛋白甲基转移酶和DNA甲基转移酶的双重抑制剂。还涉及到公式(I')的化合物,或其药用或兽药可接受的盐,或它们的立体异构体或混合物,其中 R2' 是苯基或5至6员的杂芳环,两者都可以选择与其他环融合(即公式(I)的化合物)。还涉及到含有公式(I)化合物的药用或兽药组合物。
  • [EN] NEW ANTICANCER DRUG COMBINATIONS<br/>[FR] NOUVELLES COMBINAISONS DE MÉDICAMENTS ANTICANCÉREUX
    申请人:FUNDACION PARA LA INVESTIG MEDICA APLICADA
    公开号:WO2019243236A1
    公开(公告)日:2019-12-26
    It relates to a combination comprising: A) a compound of formula (I), or a pharmaceutically or veterinary acceptable salt thereof, or any stereoisomer or mixtures of stereoisomers, either of the compound of formula (I) or of any of its pharmaceutically or veterinary acceptable salts, wherein L, X, R1, R2, R3, and R4 are as defined herein; and B) a drug selected from the group consisting of: i) an immune checkpoint inhibitor, ii) an inhibitor of an anti-apoptotic protein, and iii) a chemotherapeutic agent other than an inhibitor of an anti-apoptotic protein and an immune checkpoint inhibitor; and to pharmaceutical or veterinary compositions, and package or kit of parts comprising it. It also relates to the combination, the composition or a package or kit of parts for use in the treatment and/or prevention of cancer.
    它涉及到一种组合物,包括:A)式(I)的化合物,或其药学或兽医上可接受的盐,或者是式(I)的化合物或其药学或兽医上可接受的盐的任何立体异构体或立体异构体混合物,其中L,X,R1,R2,R3和R4如本文所定义;和B)从以下组中选择的药物:i)免疫检查点抑制剂,ii)抗凋亡蛋白的抑制剂,和iii)化疗药物,除了抗凋亡蛋白的抑制剂和免疫检查点抑制剂之外的化疗药物;以及用于治疗和/或预防癌症的药物或兽医组合物、包装或配件套件。它还涉及到该组合物、组合物或包装或配件套件,用于治疗和/或预防癌症。
  • NOVEL COMPOUNDS AS DUAL INHIBITORS OF HISTONE METHYLTRANSFERASES AND DNA METHYLTRANSFERASES
    申请人:Fundacion para la Investigacion Medica Aplicada
    公开号:EP3154957B1
    公开(公告)日:2019-11-20
  • US9840500B2
    申请人:——
    公开号:US9840500B2
    公开(公告)日:2017-12-12
查看更多